Lydi

Leading expert in hematological oncology Lydia Scarfò discusses the latest updates with the use of BTK inhibitors in CLL. Topics addressed include the management of double-refractory patients, the efficacy and toxicity of covalent and non-covalent BTK inhibitors, and the sequencing of these agents.